Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus

TARRYTOWN, N.Y., Aug. 14, 2017 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that a Phase 3 study evaluating suptavumab (REGN2222), an antibody to respiratory syncytial virus (RSV), did not mee... Biopharmaceuticals Regeneron Pharmaceuticals, suptavumab, respiratory syncytial virus, RSV
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news